友芝友生物-B(02496.HK) 发盈警,预计2024年度亏损将较上年度的1.92亿人民币减少至少35%。主要因公司与正大天晴药业订立许可与合作协议项下的交易;及上年度录得上市开支约2,460万人民币。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2024/08/29中期业绩无派息2024/03/28末期业绩无派息2023/09/28中期业绩无派息AASTOCKS新闻
Source Link友芝友生物-B(02496.HK) 发盈警,预计2024年度亏损将较上年度的1.92亿人民币减少至少35%。主要因公司与正大天晴药业订立许可与合作协议项下的交易;及上年度录得上市开支约2,460万人民币。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2024/08/29中期业绩无派息2024/03/28末期业绩无派息2023/09/28中期业绩无派息AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.